Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study

Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study

Abstract Background Recent data suggest that anti-TNF doses can be reduced in ankylosing spondylitis (AS) patients. Some authors even propose withdrawing treatment in patients in clinical remission; however, at present there is no evidence to support this. Objective To assess how long AS patients wi...

Full description

Bibliographic Details
Main Authors: Mireia Moreno, Jordi Gratacós, Vicenç Torrente-Segarra, Raimon Sanmarti, Rosa Morlà, Caridad Pontes, Maria Llop, Xavier Juanola, REMINEA study Group
Format: Article
Language:English
Published: BMC 2019-04-01
Series:Arthritis Research & Therapy
Subjects:
Ankylosing spondylitis
Anti-TNF therapy
Disease activity
Treatment withdrawal
Online Access:http://link.springer.com/article/10.1186/s13075-019-1873-3

Internet

http://link.springer.com/article/10.1186/s13075-019-1873-3

Similar Items